7 Stock Price Predictions That Are Actually Worth Listening To

Intellia Therapeutics (NTLA)

Source: Mongkolchon Akesin / Shutterstock.com

Intellia Therapeutics (NASDAQ:NTLA) fell after posting a $1.33 negative EPS. The firm has strong prospects with Apollo-B, which treats amyloidosis.

Intellia’s treatment will reduce the protein to low levels. The positive data on NTLA-2001 is a milestone. Investors should expect positive news from its ongoing Phase 1 study.

Intellia’s NTLA-2002 is an investigational therapy for the treatment of hereditary angioedema (HAE). The treatment targets the KLKB1 gene in the liver. It permanently lowers plasma kallikrein and the related activity.

NTLA-5001 is Intellia’s cell therapy for treating acute myeloid leukemia. The firm announced its first dosing on March 1. In this in vivo study, Intellia is reviewing the treatment’s efficacy and safety readout. It is studying the allogenic approach.

The company’s autologous approach to developing cell therapies costly and takes time. It cannot manufacture treatments for 50 or more people at one time. In the future, it might get there. That would introduce efficiency and would lower the cost of goods.

Leave a Reply

Your email address will not be published. Required fields are marked *